Skip to content

Pulse Biosciences, Inc. PLSE Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

LivaNova logo
LivaNovaLIVN
$14.67M+277%
AtriCure logo
AtriCureATRC
Merit Medical Systems logo
Merit Medical SystemsMMSI
Bausch Health Companies logo
Bausch Health CompaniesBHC

Other financials

Income statement

See full
Revenue$401.0K
Gross profit$31.0K
Operating income-$19.2M-6.1%
Net income-$18.6M-10.6%
EPS (diluted)-$0.49-2.1%

Balance sheet

See full
Cash & equivalents$68.3M-42.7%
Total debt$7.2M-16.6%
Total equity$66.3M-44.0%
Total assets$81.6M-38.8%

Cash flow

See full
Operating cash flow-$14.6M-7.9%
CapEx$33.0K-26.7%
Free cash flow-$14.6M-7.8%

Valuation

See full
Market cap$1.77B+38.4%

Profitability

See full
Gross margin-4,067.5%
Operating margin-10,392.1%
Net margin-9,929%
FCF margin-7,390%

Returns & leverage

See full
Return on equity-80.7%+3.1pp
Debt / equity0.1×0.0×
Current ratio7.3×-8.3×

Where this comes from

Reported directly by Pulse Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Pulse Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulse Biosciences, Inc.'s increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulse Biosciences, Inc.'s increase (decrease) in accounts receivable?
Pulse Biosciences, Inc. (PLSE) reported increase (decrease) in accounts receivable of -$55K in Q1 2026.
What is the long-term trend for Pulse Biosciences, Inc.'s increase (decrease) in accounts receivable?
Over 2 years (2021 to 2023), Pulse Biosciences, Inc.'s increase (decrease) in accounts receivable has grown at a -100.0% compound annual growth rate (CAGR), from $61K to $0.